- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07884448
PliaFX Flo Subtalar Fusion Study
A Prospective Pilot Comparative Study to Evaluate the Efficacy of PliaFX® Flo Allograft in Subtalar Arthrodesis at St. Paul's Hospital in Vancouver, Canada
During a subtalar fusion, the bones making up the subtalar joint (talus and calcaneus) are permanently fused together. In the procedure, any damaged cartilage and bone at the subtalar joint is removed, then screws are inserted into the joint to fuse the bones together. Depending on the surgeon, a bone graft is sometimes applied between the bones prior to screw insertion to aid in bone bridging (growth of bone into the fusion site). Participants who consent to this study and are assigned to the PliaFX® Flo Allograft group, will receive PliaFX® Flo Allograft (human tissue donated from a donor) at the fusion site. The PliaFX® Flo system is demineralized bone fibers (hard minerals removed from bone using acid) in a sterile syringe that allows for delivery into small areas where bone graft is needed to assist bone fusion. The allograft bone fibers are produced from donated human cadaver (deceased human) bone.
This study aims to determine whether the use of PliaFX® Flo Allograft in subtalar fusions will improve functioning and healing of the bone and cartilage for patients like you. Participants who are interested will discuss with their surgeon and be randomly assigned to one of the two study procedures below. The patient will not know what group they are in until after all data has been collected and all study visits are complete.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Première phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Biraj Bora
- Numéro de téléphone: 604-813-0889
- E-mail: biraj.bora@phc.ca
Lieux d'étude
-
-
British Colombia
-
Vancouver, British Colombia, Canada, V6Z 1Y6
- St. Paul's Hospital
-
Contact:
- Biraj Bora
- Numéro de téléphone: 604-813-0889
- E-mail: biraj.bora@phc.ca
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- The subject is at least 19 years of age.
- The subject is considered to be skeletally mature.
- The subject qualifies for subtalar fusion based on physical examination and/ or past medical history including isolated osteoarthritis, post-traumatic, degenerative, or rheumatoid arthritis of the ankle.
- The subject experiences severe pain in the subtalar joint that could not be cured with non-operative treatment options.
- The patient may undergo a subtalar fusion as part of a triple arthrodesis.
- The patient may have forefoot pathology addressed by either prior or concurrent surgery (osteotomies or fusions).
- The patient consented for either an arthroscopic or open procedure.
- The subject is able to comply with all post-operative evaluations and visits.
- The subject consents to and will receive either no graft or PliaFX® Flo allograft during their surgery
Exclusion Criteria:
-
The subject has:
- Severe osteoporosis
- Neuromuscular impairment
- Prior infection in the affected joint
-
The subject currently has acute infections that, in the opinion of the Investigator, may complicate healing.
-
The subject has a known or suspected allergy to any of the processing reagents listed in the packet insert (alcohol, glycinate buffer, and glycerol).
-
The subject is renal compromised.
-
The subject has a major risk factor for non-union (ex. poorly controlled diabetes or current smoker).
-
The subject is undergoing a revision of a prior subtalar fusion.
-
The subject has had a prior ankle joint fusion.
-
An ankle joint replacement or ankle joint fusion may be performed during the same sitting.
-
The subject has a BMI of > 50 kg/m2.
-
The subject is known to be pregnant, or plans to become pregnant during the study period
-
The investigator judges the subject to be unable or unlikely to remain compliant to follow-up due to a physical or mental condition (ex. currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.).
-
The subject is unable to provide informed consent.
-
The subject is unable to communicate with the research team.
-
The subject is unable to comply with follow-up.
-
The subject has a history of substance addiction (e.g. recreational drugs, narcotics, or alcohol) within 12 months prior to screening for study entry
-
The subject will be receiving a structural autograft or allograft (such as a femoral head graft or tri cortical iliac crest graft) to fill a defect greater than 1cm3
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Faisabilité de l'appareil
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: PliaFX Flo Allograft
Participant will receive PliaFX Flo during their Subtalar Arthrodesis procedure. |
Participant will receive the PliaFX Flo Allograft during their Subtalar Arthrodesis procedure. |
|
Aucune intervention: No Graft
Participant will receive no graft during their Subtalar Arthrodesis procedure. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Bone Bridging Percentage
Délai: Enrollment to last Follow-up visit (52 weeks)
|
Bone bridging percentage measured by CT scans at 12, 24, and 52 weeks post-operatively. |
Enrollment to last Follow-up visit (52 weeks)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Foot and Ankle Measure (FAAM) Questionnaire
Délai: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 0, maximum value of 100, and lower scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
Current Health Assessment Questionnaire
Délai: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 0, maximum value of 100, and higher scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
American Academy of Orthopaedic Surgeons (AAOS) Foot and Ankle Questionnaire
Délai: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 0, maximum value of 100, and lower scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
Demographics Questionnaire
Délai: Enrollment to last follow up visit (52 weeks)
|
Enrollment to last follow up visit (52 weeks)
|
|
|
Ankle Osteoarthritis Scale
Délai: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 1, maximum value of 100, and higher scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
SF-36 Health Survey
Délai: Enrollment to last follow up visit (52 weeks)
|
Enrollment to last follow up visit (52 weeks)
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- H26-01617
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .